



Balfour Capital Group Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference (RNAi) therapeutics—a revolutionary approach that "silences" disease-causing genes. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has developed a robust pipeline targeting both rare and prevalent diseases. Their portfolio includes approved therapies such as Onpattro, Givlaari, Oxlumo, and Amvuttra, which treat conditions like hereditary transthyretin-mediated amyloidosis (hATTR) and acute hepatic porphyria.

1. Top 5 Competitors

Alnylam operates in the competitive RNA therapeutics and rare disease markets. Key competitors include:

- Pfizer – Competes with Vyndaqel in the ATTR-CM market.
- BridgeBio Pharma – Develops ATTR-CM therapies like acoramidis.
- Ionis Pharmaceuticals – Focuses on antisense RNA therapeutics.
- Moderna – Specializes in mRNA-based therapies.
- Sarepta Therapeutics – Targets rare neuromuscular diseases.

These companies are key players in the RNA-based and rare disease therapeutic areas.

2. Largest Institutional Shareholders

As of the latest filings, major institutional shareholders of Alnylam include:

- Capital World Investors – 16.6 million shares.
- FMR LLC (Fidelity) – 13.5 million shares.
- The Vanguard Group – 13.4 million shares.
- BlackRock, Inc. – 12.5 million shares.
- Capital Research Global Investors – 11.9 million shares.

Institutional ownership stands at approximately 98.12% of total shares outstanding.

3. Management Team

- Dr. Yvonne Greenstreet, MD, MBA – Chief Executive Officer
- Dr. Kevin Fitzgerald, PhD – Chief Scientific Officer
- Dr. Pushkal Garg, MD – Chief Medical Officer and EVP, Development & Medical Affairs
- Jeffrey Poulton – Chief Financial Officer and Executive VP
- Robert Hesslein, JD – Chief Legal Officer and Corporate Secretary



Balfour Capital Group Alnylam Pharmaceuticals

4. Revenue

Alnylam reported total revenue of \$2.24 billion for the trailing twelve months ending in 2024, marking a significant increase from \$1.82 billion in 2023.

In Q1 2025, the company achieved global net product revenues of \$469 million, representing a 28% year-over-year growth.

5. Institutions with Buy Recommendations:

Several institutions have issued buy recommendations for Alnylam, including:

- Redburn Atlantic – Initiated coverage with a Buy rating.
- William Blair – Maintains an Outperform rating.
- Needham & Company – Reiterated a Buy rating with a \$320 price target.

6. Analyst Sentiment Summary

As of May 2025, analyst sentiment for Alnylam is generally positive:

- Consensus Rating: Moderate Buy
- Buy Ratings: 21
- Hold Ratings: 4
- Sell Ratings: 1
- Average Price Target: \$319.17

Some analysts express concerns about the high pricing of Amvuttra compared to competitors, which could impact market share.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, Alnylam insiders have sold a total of 251,348 shares, amounting to approximately \$60 million in value.

In the last 12 months:

- Open Market Buys: 22 transactions
- Sales: 46 transactions

In the past 3 months, corporate insiders sold shares worth approximately \$3.0 million.